Please login to the form below

Not currently logged in

metastatic hormone-sensitive prostate cancer

This page shows the latest metastatic hormone-sensitive prostate cancer news and features for those working in and with pharma, biotech and healthcare.

Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

Pfizer and Astellas have reported positive top line results from a phase 3 trial of their androgen receptor signalling inhibitor, Xtandi (enzalutamide), in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with ... The medicine is already a

Latest news

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...